July 2, 2014

New Analysis Highlights Urgent Need for Alzheimer’s Disease Drug Development

Pipeline for therapeutics is small; 99.6 percent of drug attempts fail

Alz-690×380

The number of patients with Alzheimer’s disease (AD) is going up. But few drugs are in development to treat it – while the number of available drugs is decreasing.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In a new analysis published today, researchers say there is an urgent need to increase the number of agents entering the AD drug development pipeline in order to increase the chances of some drugs making successful progress toward new therapy treatments.

The analysis, by researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health, is the first analysis of clinical trials for AD. Results appear today in the journal Alzheimer’s Research & Therapy.

The comprehensive look at all clinical trials under way shows:
• Relatively few AD drugs are in development.
• The failure rate for AD drug development is 99.6 percent from the years 2002 to 2012.
• The number of AD drugs has been declining since 2009.

“With an estimated 44 million people living worldwide with the condition, the study shows that the Alzheimer’s disease drug development ecosystem needs more support, given the magnitude of the problem.” says Jeffrey L. Cummings, MD, ScD, Director of the Lou Ruvo Center for Brain Health.

Dr. Cummings led a team of researchers who constructed a comprehensive analysis to examine all AD clinical trials since 2002. The team used the advanced search mechanisms of ClinicalTrials.gov, a government website that records all ongoing clinical trials.

Advertisement

“Our goal was to examine historical trends to help understand why Alzheimer’s disease treatment development efforts so often fail,” Dr. Cummings says.

The team of researchers included Kate Zhong, M.D., Senior Director of Clinical Research and Development at the Lou Ruvo Center for Brain Health, and Touro University medical student Travis Morstorf.

The team analyzed completed and on-going trials, as well as currently active compounds.

“The results of this analysis gave us insight into longitudinal trends in drug development,” Dr. Zhong says. “What we found was that the investment in AD drugs and therapies is relatively low compared to the challenge posed by the disease. The pipeline is almost dry.”

The analysis illustrates the high failure rate of compounds and the need for a constant supply of new drugs or a higher focus on repurposing, which can be assessed for efficacy in treating AD, the researchers say.

Advertisement

AD is more expensive to the U.S. economy than cardiovascular disease or cancer. The system of AD drugs must be supported, grown and coordinated to improve the success rate and development of new therapies, the research team says.

The researchers note the need for more repositioning studies, which involve studying an already-approved drug in a new use or condition. This would accelerate the drug development process and reduce the need to constantly invent new drugs.

One example of this is a landmark Phase IIa clinical trial to find out if bexarotene, a drug that is FDA-approved to treat skin cancer, can remove protein build-up in the brains of AD patients, as it did in a recent animal study. Researchers at the Lou Ruvo Center for Brain Health are leading this study.

For more information about clinical trials or the various programs available at Cleveland Clinic Lou Ruvo Center for Brain Health, visit ClevelandClinic.org/BrainHealthTrials or call 855.LOU.RUVO.

Related Articles

22-NEU-2959102-CQD-Hero-650×450
June 15, 2022
MINDS Study Will Assess Lifestyle Interventions for Slowing Brain Pathology in Preclinical Stages

New grant-funded investigation illustrates impact and reach of Cleveland Clinic Brain Study

22-NEU-2671014-CQD-650×450-Type
March 9, 2022
A Closer Look at the Cleveland Clinic Brain Study

How the new longitudinal investigation could become the Framingham Heart Study of brain health

20-NEU-1959738 powered-exoskeleton-for-gait-training_650x450
October 23, 2020
Study Signals Potential of Powered Exoskeleton for Gait Training in Multiple Sclerosis

Pilot findings show good patient acceptance and safety, early hints of efficacy

20-NEU-1990660-sleep-symptoms-in-health-workers-650×450
October 21, 2020
Electronic Screening for Sleep Disorders Among Healthcare Workers Is Feasible – and Sorely Needed

Study finds high prevalence of symptoms, willingness to seek treatment

20-NEU-1946228 neurofilaments_650x450
September 9, 2020
Serum Neurofilament Light as a Progressive MS Biomarker: Guideposts for the Road Ahead

Panel outlines research priorities around a promising alternative to imaging markers

20-NEU-1951118_Impella-temporary-LVAD_650x450_ (1)
September 4, 2020
Study Finds Clues to Acute Neurologic Events With Short-Term Impella Cardiac Support

Suspected factors include antithrombotic intensity, time on device, presence of thrombocytopenia

20-NEU-1929179 deep-brain-stimulation-for-TBI_650x450
September 3, 2020
Could DBS of the Cerebellar Dentate Nucleus Enhance Post-TBI Rehabilitation?

Preclinical studies will assess whether method developed for stroke recovery curbs deficits after brain injury

20-NEU-1932968-sleep-apnea-in-women_650x450
August 12, 2020
Is Upper Airway Stimulation for OSA Being Denied to Many Patients Who Can Benefit Most?

Study finds high coverage denial for women, patients with prior oral appliance use

Ad